Drug Trial Radar · NCT00094458
Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC
Last checked: Nov 20, 2026Latest source record: Feb 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
508
Actual
Start
Mar 2005
Primary completion
Apr 2008
Study completion Dec 2009
Sponsor
- Lead sponsor
- Centocor Ortho Biotech Services, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Schering-Plough
- First posted
- Oct 20, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and effectiveness of three different treatments for patients with Crohns disease who have not responded to previous treatment with a group of drugs commonly used to treat Crohn's Disease (5-ASA) and corticosteroids. Patients will receive either infliximab (a drug used to treat autoimmune diseases) or azathioprine (an immunosuppressant or drug used to suppress the immune system) or a combination of both for up to 34 weeks. This research study will involve approximately 500 patients. The main study involves up to 34 weeks (approximately 8 months). A study extension of an additional 20 weeks (approximately 5 months) is optional for patients who successfully complete the main study. A country-specific study extension of open label infliximab treatment for an additional 1 year is optional for patients who successfully complete the main study extension.
Conditions
- Crohn Disease
Interventions
infliximab infusion; AZA placebo capsBiological
Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
infliximab (IFX) infusion; azathioprine (AZA) capsOther
AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
infliximab (IFX) placebo infusion; azathioprine (AZA) capsDrug
AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Corticosteriod-free Clinical RemissionTime frame: Week 26
Locations
115 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Orange, California
Site not named
Roseville, California
Site not named
San Diego, California
Site not named
San Luis Obispo, California
Site not named
Golden, Colorado
Site not named
Littleton, Colorado
Site not named
Hartford, Connecticut
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
North Miami Beach, Florida
Site not named
Winter Park, Florida
Site not named
Austell, Georgia
Site not named
Decatur, Georgia
Site not named
Savannah, Georgia
Site not named
Peoria, Illinois
Site not named
Clive, Iowa
Site not named
Overland Park, Kansas
Site not named
Topeka, Kansas
Site not named
Baton Rouge, Louisiana
Site not named
Metairie, Louisiana
Site not named
Troy, Michigan
Site not named
Plymouth, Minnesota
Site not named
Rochester, Minnesota
Site not named
Ocean Springs, Mississippi
Site not named
Tupelo, Mississippi
Site not named
St Louis, Missouri
Site not named
Urbana, Missouri
Site not named
Lincoln, Nebraska
Site not named
Egg Harbor, New Jersey
Site not named
Great Neck, New York
Site not named
New Hyde Park, New York
Site not named
New York, New York
Site not named
Asheville, North Carolina
Site not named
Charlotte, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Wilmington, North Carolina
Site not named
Bend, Oregon
Site not named
Portland, Oregon
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.